Lumentum Holdings IncLumentum forecast first-quarter revenue above market estimates, reflecting robust demand for optical communications.
Kechuang 100 ETF Penghua rose more than 2.3% intraday, lifted by better-than-expected earnings from a US optical communications giant and clinical progress in innovative drugs, driving gains in optical communications and biopharmaceutical sectors. Lumentum forecast first-quarter net revenue for fiscal 2027 in a range of 1.23 billion to 1.28 billion US dollars, above the market estimate of 1.15 billion dollars. Coherent Corp guided next-quarter revenue at a midpoint of 2.3 billion dollars, higher than analysts' expectation of 2.14 billion dollars. In pharmaceuticals, several drugmakers disclosed new clinical advances in innovative drugs, with self-developed products spanning small molecules, peptides, biologics, siRNA, PROTAC and other technology types achieving phased breakthroughs. As of 10:14 on August 13, 2026, the SSE STAR 100 Index surged 2.56%, while Kechuang 100 ETF Penghua rose 2.36% to 1.86 yuan. Xiangcai Securities noted that innovative drug overseas expansion and value realization have become the core focus, suggesting attention to biotech companies with specific innovative drug technology platforms, integrated pharmaceutical firms, and upstream CXO and research reagent providers in the innovative drug supply chain.
Lumentum Holdings IncLumentum forecast first-quarter revenue above market estimates, reflecting robust demand for optical communications.
Coherent IncCoherent guided next-quarter revenue above analyst expectations, indicating strong demand for optical communications products.
Shenyang Chemical Industry Co Ltd
Xiangcai Co Ltd